BPC-157 vs Ziconotide (Prialt)

Molecular formula

C₆₂H₉₈N₁₆O₂₂

Molecular weight

1419.53 g/mol

Half-life

4-6 hours

Bioavailability

~100% (subcutaneous)

CAS number

137525-51-0

Molecular formula

C₁₀₂H₁₇₂N₃₆O₃₂S₇

Molecular weight

2639.2 Da

Half-life

CSF: 4.6 hours; Plasma: 1.3 hours

Bioavailability

100% intrathecal; does not cross blood-brain barrier systemically

CAS number

107452-89-1

Common

• Injection site redness
• Mild nausea
• Dizziness

Uncommon

• Headache
• Fatigue
• Hot/cold sensations

Serious

• Allergic reaction

Common

• Dizziness
• Nausea

Uncommon

• Confusion and Memory Impairment
• Ataxia and Nystagmus

Serious

• Psychiatric Symptoms
• Elevated Creatine Kinase and Rhabdomyolysis
• Psychiatric Symptoms
• Rhabdomyolysis with Acute Renal Failure

Evidence level

Strong preclinical (extensive animal studies)

FDA status

Research compound

Safety overview

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

• Pregnancy
• Breastfeeding
• Active cancer
• History of cancer

Evidence level

Strong human trials (Phase 3 or FDA approved)

FDA status

FDA approved (PRIALT, 2004) for the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, including intrathecal morphine. Carries a BOXED WARNING for neuropsychiatric adverse reactions and is contraindicated in anyone with a pre-existing history of psychosis.

Safety overview

PRIALT carries a BOXED WARNING for neuropsychiatric adverse reactions: severe psychiatric symptoms and neurological impairment may occur, every patient must be monitored frequently for cognitive impairment, hallucinations or changes in mood or consciousness, and therapy must be discontinued if serious neurological or psychiatric signs appear. It is CONTRAINDICATED in anyone with a pre-existing history of psychosis [6]. The reported rates are specific: hallucinations 12%, paranoid reactions 3%, hostility 2%, delirium 2%, psychosis 1%, manic reactions 0.4%. The label also states that ziconotide may cause or worsen depression with risk of suicide in susceptible patients, and that the placebo-controlled trials showed a HIGHER incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo [6]. Beyond the box, the label warns about meningitis — patients and carers must know the signs, including fever, headache, stiff neck, altered mental status, nausea or vomiting and occasionally seizures — about patients becoming unresponsive or stuporous, about elevations in creatine kinase requiring periodic monitoring, and about opiate withdrawal: patients must NOT be abruptly withdrawn from their opiates but tapered over a few weeks and replaced with an equivalent oral dose [6]. Ziconotide itself can be stopped abruptly without withdrawal effects [6].

Contraindications

• A pre-existing history of psychosis — stated in the boxed warning and in the contraindications
• Known hypersensitivity to ziconotide or any formulation component
• Any concomitant treatment or medical condition that would make intrathecal administration hazardous
• Infection at the microinfusion injection site
• Uncontrolled bleeding diathesis
• Spinal canal obstruction that impairs circulation of cerebrospinal fluid